Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Portfolio Pulse from
Innate Pharma has received Breakthrough Therapy Designation from the U.S. FDA for its drug lacutamab, aimed at treating relapsed or refractory Sézary Syndrome.
February 17, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's drug lacutamab has been granted Breakthrough Therapy Designation by the FDA for treating relapsed or refractory Sézary Syndrome, potentially accelerating its development and approval process.
The FDA's Breakthrough Therapy Designation is a significant regulatory milestone that can expedite the development and review process of lacutamab. This news is likely to positively impact Innate Pharma's stock price as it indicates potential for faster market entry and increased investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100